Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navicixizumab with or without paclitaxel versus paclitaxel in platinum-resistant ovarian, primary peritoneal, or fallopian tube cancer
2021-001933-38Phase 3Terminated
- Sponsor
- OncXerna Therapeutics
- Start
- Nov 2021
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) comparing Navicixizumab + paclitaxel, Navicixizumab monotherapy and Paclitaxel monotherapy (3 arms). Primary endpoint: Objective response rate. Started Nov 2021; status: terminated.
02
Drugs
navicixizumabpaclitaxel
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on 2021-001933-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001933-38.